Evidence map›Paper›PMID 35154099›Full record

ArticleFrontiers in immunology2022

Glucagon-Like Peptide-1 Receptor Regulates Macrophage Migration in Monosodium Urate-Induced Peritoneal Inflammation.

Jun Chen, Aihua Mei, Xinxin Liu, Zachary Braunstein, Yingying Wei, Biao Wang, Lihua Duan, Xiaoquan Rao, Sanjay Rajagopalan, Lingli Dong and 1 more

Erratum issuedOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
3.3field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Semaglultide targets Spp1Journal of neuroinflammation · 2025
    Article
  7. Review
  8. Article
  9. Review
  10. The Role of Glucagon-Like Peptide-1 Receptor Agonists in Chronic Obstructive Pulmonary Disease.International journal of chronic obstructive pulmonary disease · 2023
    Review
  11. Article
  12. Review
  13. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 2 countries.

Jun ChenSinopharm Dongfeng General Hospital, Hubei University of Medicine, Hubei Key Laboratory of Wudang Local Chinese Medicine Research (Hubei University of Medicine), Shiyan, China.
Aihua MeiSinopharm Dongfeng General Hospital, Hubei University of Medicine, Hubei Key Laboratory of Wudang Local Chinese Medicine Research (Hubei University of Medicine), Shiyan, China.
Xinxin LiuDepartment of Rheumatology and Immunology, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China.
Zachary BraunsteinDepartment of Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, United States.
Yingying WeiCardiovascular Research Institute, Case Western Reserve University, Cleveland, OH, United States.
Biao WangCardiovascular Research Institute, Case Western Reserve University, Cleveland, OH, United States.
Lihua DuanCardiovascular Research Institute, Case Western Reserve University, Cleveland, OH, United States.
Xiaoquan RaoDepartment of Cardiology, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China.
Sanjay RajagopalanCardiovascular Research Institute, Case Western Reserve University, Cleveland, OH, United States.
Lingli DongDepartment of Rheumatology and Immunology, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China.
Jixin ZhongDepartment of Rheumatology and Immunology, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China.
Case Western Reserve University · USHuazhong University of Science and Technology · CNTongji Hospital · CNChina National Pharmaceutical Group Corporation (China) · CNThe Ohio State University Wexner Medical Center · US

Funding

Role of DPP4-ADA interaction in obesity-induced inflammationR03DK119680 · NIDDK · CASE WESTERN RESERVE UNIVERSITY · PI ZHONG, JIXIN · 2019 to 2020
$154k
A role of DPP4 in T cell trafficking and vascular inflammationR01HL142643 · NHLBI · CASE WESTERN RESERVE UNIVERSITY · PI ZHONG, JIXIN · 2020 to 2020
$21k
NHLBI NIH HHS R01 HL142643NIDDK NIH HHS R03 DK119680
6 · The paper itself

Abstract

Glucagon-like peptide-1 (GLP-1) is an insulinotropic peptide that signals through the GLP-1 receptor (GLP-1R). GLP-1R, therefore, plays a critical role in diabetes and cardiovascular disease. Whether GLP-1R is involved in inflammatory disease such as gout remains unclear. Macrophages are critical effector cells in the pathogenesis of gout, a common form of inflammatory arthritis caused by the deposition of uric acid in joints. The expression of GLP-1R at the protein level is controversial due to the lack of specificity of existing antibodies against GLP-1R. Using a transgenic mouse model expressing enhanced green fluorescent protein (EGFP) under the control of GLP-1R promoter, here we confirmed the expression of GLP-1R by macrophages. M2 type macrophages and Ly6C

Indexed as

Gene Expression RegulationAnimalsCell MovementDisease Models, AnimalGlucagon-Like Peptide-1 ReceptorInflammationMacrophagesMaleMiceMice, Inbred C57BLMice, KnockoutMice, TransgenicNeutrophilsPeritonitisUric AcidGlucagon-Like Peptide-1 ReceptorUric AcidGLP-1, glucagon-like peptide-1goutinflammationmacrophagemonosodium urate

Identifiers

PMID35154099
PMCPMC8828485
OpenAlexW4210805671

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.